GPT Healthcare Q2 FY27: Revenue up 14.1% to ₹135.6 Cr, PAT soars 45.2% to ₹15.4 Cr
GPT Healthcare reported Q2 FY27 revenue of ₹135.6 Cr, up 14.1% YoY, with PAT at ₹15.4 Cr, up 45.2%. H1 FY27 revenue grew 15.8% to ₹261.8 Cr, and PAT rose 53.9% to ₹28.1 Cr. Occupancy improved to 50.3% in Q2. The company plans to open a new hospital in Jamshedpur by April 2027.
The strong financial performance, coupled with strategic growth initiatives like new hospital openings and technological advancements, is expected to have a significant positive impact on the company's market position and investor confidence.
The company reported strong year-on-year growth in revenue and profit, alongside improved margins and occupancy rates. Investments in new technologies and facilities, as well as expansion plans, indicate a positive outlook.
GPT Healthcare Limited announced its financial results for the second quarter and half year ended September 30, 2026. The company reported a 14.1% year-on-year increase in revenue from operations to ₹135.6 crore for Q2 FY27. EBITDA grew by 23.9% to ₹29.8 crore, with EBITDA margins expanding to 21.5% from 20% in the prior year. Profit After Tax (PAT) saw a significant jump of 45.2% to ₹15.4 crore, with PAT margins improving to 11.1% from 8.8%. ARPOB for the quarter stood at ₹40,721, a 7.1% year-on-year increase, and network occupancy improved to 50.3% from 47.4%.
For the half year ended September 30, 2027 (H1 FY27), revenue from operations increased by 15.8% year-on-year to ₹261.8 crore. EBITDA grew by 30.3% to ₹56 crore, with margins improving to 21% from 18.8%. PAT increased by 53.9% to ₹28.1 crore, with PAT margins at 10.5%. ARPOB for H1 stood at ₹41,490, and network occupancy was 47.9%.
The company highlighted operational progress across its network, including the introduction of robotic-assisted surgery at ILS Salt Lake and ILS Howrah, and investments in oncology and diagnostic infrastructure. ILS Salt Lake achieved 65.4% occupancy in H1 and crossed 850 robotic surgeries. ILS Dum Dum, the largest revenue contributor, recorded revenue of ₹84.8 crore with 69.4% occupancy and commenced a cardiothoracic and vascular surgery unit. ILS Agartala strengthened its oncology program, performing over 3,200 radiation therapy procedures and 1,000 PET scans. ILS Howrah saw revenue growth of 25% in H1 and launched a MAKO robotic knee surgery system.
The newest facility, ILS Raipur, achieved NABH accreditation and performed its first TAVI and liver transplant procedures in Q2 FY27. The company expects Raipur to break even on a monthly basis by Q1 FY28, with H1 FY27 losses at ₹6.5 crore. The Jamshedpur project, a 155-bed tertiary care hospital, is on track for operations in March-April 2027.
Looking ahead, GPT Healthcare aims for ROE and ROCE of approximately 25%. The company anticipates FY27 to see around 15% to 16% growth over the previous year. Lease expenses for Raipur are approximately ₹4 crore annually, with Jamshedpur expected to be similar.
What to do with a filing like this
GPT Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by GPT Healthcare Limited. Read the original for the full detail.